Seres Therapeutics (MCRB) Earnings Analysis
Seres Therapeutics (MCRB) has no confirmed upcoming earnings date. Last quarter (2026-03-12) it beat with EPS -1.89 USD vs -2.39 USD est (+20.9%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -1.02.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does MCRB next report earnings?
No confirmed upcoming earnings date is currently scheduled for MCRB. This page updates as the calendar is published.
MCRB earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-12 | -1.89 USD | -2.39 USD | +20.9% | Beat |
| 2025-03-13 | -0.32 USD | -0.17 USD | -88.2% | Miss |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
MCRB valuation and analyst view
| Trailing P/E | -1.02 |
|---|---|
| Trailing EPS | -4.89422 USD |
| Price / book | 1.91 |
| Dividend yield | 0.00% |
| Market cap | 0.05B |
| Analyst consensus | Buy (11 buy / 3 hold / 4 sell) |
| Avg price target | 12 USD |
Related research pages
Frequently asked questions
When is Seres Therapeutics (MCRB)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for MCRB. This page updates as the calendar is published.
Did MCRB beat earnings last quarter?
In its 2026-03-12 report, MCRB posted EPS of -1.89 USD versus a -2.39 USD estimate — a beat of 20.9%.
What is MCRB's earnings track record?
Over the last 2 reported quarters with consensus data, MCRB beat estimates 1 times (50%).
What is MCRB's current P/E ratio and EPS?
MCRB trades at a trailing P/E of -1.02 on trailing EPS of -4.894217426644917 USD.
What do analysts rate MCRB?
Analyst consensus is "Buy" across 18 ratings (0 strong buy, 11 buy, 3 hold, 4 sell, 0 strong sell). Average 12-month price target: 12 USD.